Orthofix Q3 2026 Earnings Call - ORTHOFIX MEDICAL INC

Explicit Guidance:

• Full-Year 2026 Pro Forma Net Sales: Expected range of $825 million to $830 million (previously adjusted for Q3 softness, supplier delays, FX, and international limb reconstruction timing).
• Full-Year 2026 Non-GAAP Adjusted EBITDA: Expected range of $86 million to $88 million (impacted by lower revenue and unfavorable geographic mix, partially offset by cost discipline and lower incentive compensation).
• Q4 2026 Specifics: Anticipates sequential growth driven by normal seasonality and recognition of ~$15 million in net sales related to the European Distributor Arrangement.
• 2027 Guidance: Formal guidance to be provided on the Q4 2026 earnings call.
• 2027 Headwinds: The European MDR strategy is expected to create an approximate $22 million net sales headwind in 2027 while requirements are completed; this is a temporary regulatory timing impact on revenue recognition, not a change in underlying demand.
• Currency Assumption: The outlook does not contemplate additional foreign exchange rate changes for the remainder of 2026.

Business-Segment Outlook:

• U.S. Spine: Prioritizing improvement in commercial execution, inventory availability, and instrument set productivity. Expecting a "choppy" transition over the coming quarters with a four-quarter impact reflected in guidance. Focus on stabilizing supply chains and consolidating around the top 30 distributors (who grow above market) while exiting lower-performing relationships.
• Product Launches: Full market launch of the Virada spinal implant system for open procedures expected later in Q4 2026. Anticipates a full quarter of Virada launch contribution in Q1 2027.
• U.S. Biologics: Business expected to continue stabilizing after Q3 flat performance; October showed positive year-over-year growth. Priority on account execution, higher utilization, and focus on priority products like OsteoCov.
• Limb Reconstruction: International demand driving growth. FITBON and TRULOC Elevate platforms are expected to drive franchise growth (each grew >20% in Q3).
• Therapeutic Solutions: Expected to sustain steady revenue growth, strong margins, and cash generation (4% volume growth in Q3). Focus on improving prescription conversion via digital capabilities (AXEL STEAM 2.0, STEAM OnTrack).
• Innovation: Continued investment in Limb Reconstruction, including a submitted 510K for an automated TRULOC Elevate system (September) and pursuit of new indications such as diabetic foot ulcers. 7D navigation system received two additional 510K clearances for software enhancements.

Market and Competitive Outlook:

• Distributor Network: Strategy to concentrate resources behind strongest partners who now generate ~80% of U.S. spinal implant revenue. Core partners' consigned assets turn over 20% faster than loaner-heavy models.
• Market Dynamics: Acknowledges near-term pressure from market softness in procedural volumes at top accounts and supply chain disruptions. Believes core distributors are growing "well above the market," indicating performance is not driven by market share loss in the core.
• Supply Chain: Unplanned supplier delays (specifically regarding inter-bodies and instrument manufacturing) causing near-term constraints; expects fixes to be in place by end of Q4 to support 2027 launch and sales.
• Competition/Positioning: Expecting to maintain market share in core accounts while simplifying the portfolio to focus on differentiated platforms with high growth potential.

Macro / Industry Outlook:

• Foreign Exchange: Acknowledged FX headwinds impacting Q3 and full-year outlook; does not expect further changes in 2026 but expects them to be a factor in 2027 (specifically the MDR impact).
• Regulatory: European MDR requirements are creating a temporary $22 million net sales headwind in 2027 due to revenue recognition timing, not a decline in demand.
• Economic/Procedural: Observing a softer market-driven procedural environment in the U.S. spine market.

Strategic Initiatives:

• Portfolio Rationalization: Accelerating exits from non-strategic, lower-performing distributor relationships (representing ~20% of business) to simplify the network and reduce support costs.
• Capital Allocation: Redirecting inventory, capital, and commercial support to differentiated platforms (Virada, 7D, FITBON, TRULOC Elevate) and highest-value technologies.
• Cash Management: European Distributor Arrangement creates a temporary free cash flow timing headwind in 2026 (inventory outflows now, receipts in 2027) but does not alter long-term earnings power.
• Cost Discipline: Aligning organizational resources to reduce support costs and redirect savings toward growth opportunities.

Risks and Headwinds to Outlook:

• Execution & Transition: The transition of exiting distributors and redeploying assets is expected to unfold over the coming quarters with a four-quarter impact on sales and margins.
• Supply Chain: Continued supplier delays or instrument set constraints could impact the ability to support demand among top distributors.
• Market Softness: Unforeseen weakness in procedural volumes at top accounts.
• Regulatory Timing: The MDR headwind is temporary but creates a specific revenue recognition gap in 2027.
• Cash Flow: The European MDR/Distributor arrangement creates a temporary negative working capital impact in 2026 despite positive long-term economics.

Management Tone on the Future:

• Confidence Level: Expresses "clear recovery plan" and confidence that actions are underway to stabilize the business, though acknowledges the path involves near-term pressure.
• Strategic Consistency: Emphasizes that the core strategy is "not changing" despite temporary market dynamics and supply issues; reiterates belief that long-term actions are paying off.
• Caveats: Management hedges on specific 2027 run-rates, stating it is "early to comment" on exact spine performance due to the MDR headwind and supplier recovery timing.
• Outlook for 2027: Expects to be "pretty well positioned" for 2027, with core revenue (excluding MDR) expected to be in positive territory once supplier issues are resolved and Virada is fully launched.

Miscellaneous:

• Earnings Call Timing: Formal 2027 guidance will be provided on the Q4 2026 earnings call.
• Long-Term Targets: No commitment yet made regarding the reintroduction of longer-range financial targets (LRP) beyond 2027.
• Non-GAAP Measures: All forward-looking financial guidance is provided on a non-GAAP, pro forma, constant currency basis, excluding discontinued M6 product lines.